메뉴 건너뛰기




Volumn 20, Issue 2, 2015, Pages 148-156

Efficacy of levomilnacipran extended-release in major depressive disorder: Pooled analysis of 5 double-blind, placebo-controlled trials

Author keywords

antidepressant; levomilnacipran; major depressive disorder; remission; response; serotonin and norepinephrine reuptake inhibitor

Indexed keywords

MILNACIPRAN; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; DELAYED RELEASE FORMULATION;

EID: 84995350667     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000273     Document Type: Article
Times cited : (16)

References (36)
  • 1
    • 84875465140 scopus 로고    scopus 로고
    • The epidemiology of depression across cultures
    • Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013; 34: 119-138.
    • (2013) Annu Rev Public Health , vol.34 , pp. 119-138
    • Kessler, R.C.1    Bromet, E.J.2
  • 2
    • 0037831023 scopus 로고    scopus 로고
    • The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (NCS-R)
    • Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA. 2003; 289(23): 3095-3105.
    • (2003) JAMA , vol.289 , Issue.23 , pp. 3095-3105
    • Kessler, R.C.1    Berglund, P.2    Demler, O.3
  • 3
    • 33846050551 scopus 로고    scopus 로고
    • Prevalence of psychiatric disorders across Latino subgroups in the United States
    • Alegria M, Mulvaney-Day N, Torres M, Polo A, Cao Z, Canino G. Prevalence of psychiatric disorders across Latino subgroups in the United States. Am J Public Health. 2007; 97(1): 68-75.
    • (2007) Am J Public Health , vol.97 , Issue.1 , pp. 68-75
    • Alegria, M.1    Mulvaney-Day, N.2    Torres, M.3    Polo, A.4    Cao, Z.5    Canino, G.6
  • 4
    • 80555142935 scopus 로고    scopus 로고
    • Major depressive disorder in the African American population
    • Bailey RK, Patel M, Barker NC, Ali S, Jabeen S. Major depressive disorder in the African American population. J Natl Med Assoc. 2011; 103(7): 548-557.
    • (2011) J Natl Med Assoc , vol.103 , Issue.7 , pp. 548-557
    • Bailey, R.K.1    Patel, M.2    Barker, N.C.3    Ali, S.4    Jabeen, S.5
  • 5
    • 76649118757 scopus 로고    scopus 로고
    • The associations between socio-economic status and major depressive disorder among blacks, Latinos, Asians and non-Hispanic whites: Findings from the collaborative psychiatric epidemiology studies
    • Gavin AR, Walton E, Chae DH, Alegria M, Jackson JS, Takeuchi D. The associations between socio-economic status and major depressive disorder among blacks, Latinos, Asians and non-Hispanic whites: findings from the collaborative psychiatric epidemiology studies. Psychol Med. 2010; 40(1): 51-61.
    • (2010) Psychol Med , vol.40 , Issue.1 , pp. 51-61
    • Gavin, A.R.1    Walton, E.2    Chae, D.H.3    Alegria, M.4    Jackson, J.S.5    Takeuchi, D.6
  • 6
    • 35748945434 scopus 로고    scopus 로고
    • Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's world mental health survey initiative
    • Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's world mental health survey initiative. World Psychiatry. 2007; 6 (3): 168-176.
    • (2007) World Psychiatry , vol.6 , Issue.3 , pp. 168-176
    • Kessler, R.C.1    Angermeyer, M.2    Anthony, J.C.3
  • 7
    • 79960659664 scopus 로고    scopus 로고
    • Cross-national epidemiology of DSM-IV major depressive episode
    • Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011; 9: 90.
    • (2011) BMC Med , vol.9 , pp. 90
    • Bromet, E.1    Andrade, L.H.2    Hwang, I.3
  • 8
    • 71649092235 scopus 로고    scopus 로고
    • Health related quality of life in recurrent depression: A comparison with a general population sample
    • ten Doesschate MC, Koeter MW, Bockting CL, Schene AH. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1-3): 126-132.
    • (2010) J Affect Disord , vol.120 , Issue.1-3 , pp. 126-132
    • Ten Doesschate, M.C.1    Koeter, M.W.2    Bockting, C.L.3    Schene, A.H.4
  • 9
    • 30044433660 scopus 로고    scopus 로고
    • Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: Implications for clinical practice
    • Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28-40.
    • (2006) Am J Psychiatry , vol.163 , Issue.1 , pp. 28-40
    • Trivedi, M.H.1    Rush, A.J.2    Wisniewski, S.R.3
  • 10
    • 77952371046 scopus 로고    scopus 로고
    • Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder
    • Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol. 2010; 30(3): 294-299.
    • (2010) J Clin Psychopharmacol , vol.30 , Issue.3 , pp. 294-299
    • Kornstein, S.G.1    Clayton, A.H.2    Soares, C.N.3    Padmanabhan, S.K.4    Guico-Pabia, C.J.5
  • 11
    • 84855946303 scopus 로고    scopus 로고
    • The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder
    • Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012; 28(1): 27-39.
    • (2012) Curr Med Res Opin , vol.28 , Issue.1 , pp. 27-39
    • Reed, C.R.1    Kajdasz, D.K.2    Whalen, H.3    Athanasiou, M.C.4    Gallipoli, S.5    Thase, M.E.6
  • 12
    • 79551586265 scopus 로고    scopus 로고
    • Examining the role of race and ethnicity in relapse rates of major depressive disorder
    • Trinh NH, Shyu I, McGrath PJ, et al. Examining the role of race and ethnicity in relapse rates of major depressive disorder. Compr Psychiatry. 2011; 52(2): 151-155.
    • (2011) Compr Psychiatry , vol.52 , Issue.2 , pp. 151-155
    • Trinh, N.H.1    Shyu, I.2    McGrath, P.J.3
  • 13
    • 84882847258 scopus 로고    scopus 로고
    • Treatment response for acute depression is not associated with number of previous episodes: Lack of evidence for a clinical staging model for major depressive disorder
    • Dodd S, Berk M, Kelin K, Mancini M, Schacht A. Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. J Affect Disord. 2013; 150(2): 344-349.
    • (2013) J Affect Disord , vol.150 , Issue.2 , pp. 344-349
    • Dodd, S.1    Berk, M.2    Kelin, K.3    Mancini, M.4    Schacht, A.5
  • 14
    • 84860758903 scopus 로고    scopus 로고
    • Is prior course of illness relevant to acute or longer-term outcomes in depressed outpatients? A STAR∗D report
    • Rush AJ, Wisniewski SR, Zisook S, et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed outpatients? A STAR∗D report. Psychol Med. 2012; 42(6): 1131-1149.
    • (2012) Psychol Med , vol.42 , Issue.6 , pp. 1131-1149
    • Rush, A.J.1    Wisniewski, S.R.2    Zisook, S.3
  • 15
    • 84875936452 scopus 로고    scopus 로고
    • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report
    • Sung SC, Wisniewski SR, Balasubramani GK, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol Med. 2013; 43(5): 945-960.
    • (2013) Psychol Med , vol.43 , Issue.5 , pp. 945-960
    • Sung, S.C.1    Wisniewski, S.R.2    Balasubramani, G.K.3
  • 16
    • 57049148576 scopus 로고    scopus 로고
    • Factors predicting reduced antidepressant response: Experience with the SNRI duloxetine in patients with major depression
    • Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008; 20(4): 209-218.
    • (2008) Ann Clin Psychiatry , vol.20 , Issue.4 , pp. 209-218
    • Howland, R.H.1    Wilson, M.G.2    Kornstein, S.G.3
  • 17
    • 34447321014 scopus 로고    scopus 로고
    • Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression
    • Shelton RC, Prakash A, Mallinckrodt CH, et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract. 2007; 61(8): 1337-1348.
    • (2007) Int J Clin Pract , vol.61 , Issue.8 , pp. 1337-1348
    • Shelton, R.C.1    Prakash, A.2    Mallinckrodt, C.H.3
  • 19
    • 84555194678 scopus 로고    scopus 로고
    • Efficacy of antidepressants for late-life depression: A meta-analysis and meta-regression of placebo-controlled randomized trials
    • Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011; 72(12): 1660-1668.
    • (2011) J Clin Psychiatry , vol.72 , Issue.12 , pp. 1660-1668
    • Tedeschini, E.1    Levkovitz, Y.2    Iovieno, N.3    Ameral, V.E.4    Nelson, J.C.5    Papakostas, G.I.6
  • 20
    • 77952569120 scopus 로고    scopus 로고
    • Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder
    • Okuda A, Suzuki T, Kishi T, et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010; 64(3): 268-273.
    • (2010) Psychiatry Clin Neurosci , vol.64 , Issue.3 , pp. 268-273
    • Okuda, A.1    Suzuki, T.2    Kishi, T.3
  • 21
    • 3042517258 scopus 로고    scopus 로고
    • One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies
    • Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004; 56 (1): 46-53.
    • (2004) Biol Psychiatry , vol.56 , Issue.1 , pp. 46-53
    • Rush, A.J.1    Trivedi, M.2    Carmody, T.J.3
  • 22
  • 23
  • 24
    • 84876993979 scopus 로고    scopus 로고
    • Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
    • Auclair AL, Martel JC, Assie MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013; 70: 338-347.
    • (2013) Neuropharmacology , vol.70 , pp. 338-347
    • Auclair, A.L.1    Martel, J.C.2    Assie, M.B.3
  • 25
    • 84875475046 scopus 로고    scopus 로고
    • The efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: A phase 3, randomized, double-blind, placebo-controlled study
    • Asnis G, Bose A, Gommoll C, Chen C, Greenberg WM. The efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013; 74(3): 242-248.
    • (2013) J Clin Psychiatry , vol.74 , Issue.3 , pp. 242-248
    • Asnis, G.1    Bose, A.2    Gommoll, C.3    Chen, C.4    Greenberg, W.M.5
  • 26
    • 84891816383 scopus 로고    scopus 로고
    • Levomilnacipran ER 40mg and 80mg in patients with major depressive disorder: A phase III, randomized, double-blind, fixed-dose, placebo-controlled study
    • Bakish D, Bose A, Gommoll C, et al. Levomilnacipran ER 40mg and 80mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014; 39(1): 40-49.
    • (2014) J Psychiatry Neurosci , vol.39 , Issue.1 , pp. 40-49
    • Bakish, D.1    Bose, A.2    Gommoll, C.3
  • 27
    • 84895860088 scopus 로고    scopus 로고
    • A randomized double-blind, placebo-controlled, study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder
    • Gommoll C, Greenberg WM, Chen C. A randomized double-blind, placebo-controlled, study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. Journal of Drug Assessment. 2014; 3: 10-19.
    • (2014) Journal of Drug Assessment , vol.3 , pp. 10-19
    • Gommoll, C.1    Greenberg, W.M.2    Chen, C.3
  • 28
    • 84891737410 scopus 로고    scopus 로고
    • A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder
    • Sambunaris A, Bose A, Gommoll C, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014; 34(1): 47-56.
    • (2014) J Clin Psychopharmacol , vol.34 , Issue.1 , pp. 47-56
    • Sambunaris, A.1    Bose, A.2    Gommoll, C.3
  • 29
    • 84876570587 scopus 로고    scopus 로고
    • The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: A randomized, double-blind, placebo-controlled, proof-of-concept study
    • Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D. The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013; 74(4): 363-369.
    • (2013) J Clin Psychiatry , vol.74 , Issue.4 , pp. 363-369
    • Montgomery, S.A.1    Mansuy, L.2    Ruth, A.3    Bose, A.4    Li, H.5    Li, D.6
  • 31
    • 67649206008 scopus 로고    scopus 로고
    • Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    • Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009; 24(3): 111-118.
    • (2009) Int Clin Psychopharmacol , vol.24 , Issue.3 , pp. 111-118
    • Montgomery, S.A.1    Moller, H.J.2
  • 32
    • 3142554206 scopus 로고    scopus 로고
    • Implications of using different cut-offs on symptom severity scales to define remission from depression
    • Zimmerman M, Posternak MA, Chelminski I. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol. 2004; 19(4): 215-220.
    • (2004) Int Clin Psychopharmacol , vol.19 , Issue.4 , pp. 215-220
    • Zimmerman, M.1    Posternak, M.A.2    Chelminski, I.3
  • 33
    • 41549125307 scopus 로고    scopus 로고
    • Sex differences in depression symptoms in treatment-seeking adults: Confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study
    • Marcus SM, Kerber KB, Rush AJ, et al. Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry. 2008; 49(3): 238-246.
    • (2008) Compr Psychiatry , vol.49 , Issue.3 , pp. 238-246
    • Marcus, S.M.1    Kerber, K.B.2    Rush, A.J.3
  • 34
    • 50349087007 scopus 로고    scopus 로고
    • Efficacy of second generation antidepressants in late-life depression: A meta-analysis of the evidence
    • Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008; 16(7): 558-567.
    • (2008) Am J Geriatr Psychiatry , vol.16 , Issue.7 , pp. 558-567
    • Nelson, J.C.1    Delucchi, K.2    Schneider, L.S.3
  • 35
    • 19244374612 scopus 로고    scopus 로고
    • Differentiating moderate and severe depression using the Montgomery-Asberg Depression Rating Scale (MADRS)
    • Müller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg Depression Rating Scale (MADRS). J Affect Disord. 2003; 77(3): 255-260.
    • (2003) J Affect Disord , vol.77 , Issue.3 , pp. 255-260
    • Müller, M.J.1    Himmerich, H.2    Kienzle, B.3    Szegedi, A.4
  • 36
    • 57049188862 scopus 로고    scopus 로고
    • Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
    • Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009; 19(1): 34-40.
    • (2009) Eur Neuropsychopharmacol , vol.19 , Issue.1 , pp. 34-40
    • Papakostas, G.I.1    Fava, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.